Dean O. Takaoka

Array ( [id] => 15831769 [patent_doc_number] => 20200131166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => BENZISOXAZOLES [patent_app_type] => utility [patent_app_number] => 16/727101 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16727101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993357 [patent_doc_number] => 20200172549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => NOVEL CHLORIN E6-CURCUMIN DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/724703 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15765721 [patent_doc_number] => 20200113878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => PYRAZOLO[4,3-C]Quinoline Derivatives For Inhibition Of Beta-Glucuronidase [patent_app_type] => utility [patent_app_number] => 16/711623 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 308 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16711623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16908921 [patent_doc_number] => 11040946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Bromonaphthalimide compounds and phosphorescent liquid formulation thereof [patent_app_type] => utility [patent_app_number] => 16/712265 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 5171 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16176875 [patent_doc_number] => 20200223843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/710074 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15589545 [patent_doc_number] => 20200071307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS [patent_app_type] => utility [patent_app_number] => 16/681763 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16390905 [patent_doc_number] => 20200331846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/680674 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586273 [patent_doc_number] => 20200069671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/674546 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16674546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681107 [patent_doc_number] => 20200095217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/655784 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 363 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15742361 [patent_doc_number] => 20200110069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/601198 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16601198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363531 [patent_doc_number] => 20200017530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => MUSCARINIC RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 16/584185 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15407915 [patent_doc_number] => 20200024279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A BENZOTRIAZOLE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/583869 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16583869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696651 [patent_doc_number] => 10947231 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Processes for the preparation of substituted tetrahydro beta-carbolines [patent_app_type] => utility [patent_app_number] => 16/580078 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9290 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321223 [patent_doc_number] => 10781179 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => (-)-huperzine A processes and related compositions and methods of treatment [patent_app_type] => utility [patent_app_number] => 16/571720 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 3 [patent_no_of_words] => 18922 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16571720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15320929 [patent_doc_number] => 20200000794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => BENZOQUINOLONE INHIBITORS OF VMAT2 [patent_app_type] => utility [patent_app_number] => 16/568666 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16198561 [patent_doc_number] => 10723711 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors [patent_app_type] => utility [patent_app_number] => 16/547037 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67967 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16547037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770810 [patent_doc_number] => 10981898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity [patent_app_type] => utility [patent_app_number] => 16/535931 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78393 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 616 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16028117 [patent_doc_number] => 10676465 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => GLP-1 receptor agonists and uses thereof [patent_app_type] => utility [patent_app_number] => 16/535616 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 49183 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770810 [patent_doc_number] => 10981898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity [patent_app_type] => utility [patent_app_number] => 16/535931 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78393 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 616 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267307 [patent_doc_number] => 20190382387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => GLP-1 Receptor Agonists and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/535553 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49096 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535553 [rel_patent_id] =>[rel_patent_doc_number] =>)